Table I: Higher Oncogenic Risk For Non-Calcineurin Comparators: Results From Randomized Controlled Trials
|
Randomized Controlled Trials of Pimecrolimus5 |
Randomized Controlled Trials of Tacrolimus6 |
||
|
Pimecrolimus (n=19,000) |
Vehicle (V) or Corticosteroid (C) (n=4,000) |
Tacrolimus (n=4,200) |
Vehicle (V) or Corticosteroid (C) (n=2,300) |
|
Squamous cell carcinoma of skin |
Gastric cancer (C) |
No Cancers |
Basal Cell Carcinoma (V) |
|
Colon cancer |
Melanoma (C) |
|
Squamous Cell Carcinoma of Skin (C) |
|
|
Malignant Histiocytosis X (C) |
Giant Cell Lymphoma (C) |
|
|
Acute Lymphocytic Leukemia (C) |
|
||
|
Thyroid Cancer (V) |
|||
|
Odds Ratio That Corticosteroids Or Vehicle Are More Oncogenic Than Pimecrolimus = 11.9 |
Odds Ratio That Corticosteroids Or Vehicle Are More Oncogenic Than Tacrolimus = Infinite |
||